Friday, November 6, 2020
- 9:00AM-11:00AM
-
Abstract Number: 0369
Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0345
Effectiveness and Safety of Apremilast in Biologic-Naive versus Biologic-Experienced Patients with Psoriatic Arthritis in Real-World Clinical Practice Settings in Germany: Interim Analysis of an Ongoing, Multicenter, Prospective, Non-interventional Study
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0107
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
Osteoporosis & Metabolic Bone Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 0208
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0217
Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0380
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0352
Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naïve Patients with Psoriatic Arthritis: 52-Week Results
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0211
Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0375
Efficacy of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0363
Efficacy of Ixekizumab on Disease Activity and Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis and Objective Signs of Inflammation, Stratified by Baseline CRP/Sacroiliac Joint MRI Status
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0224
Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0381
Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0059
EHR-Supported Staff Protocol Improves Smoking Cessation in a Diverse Rheumatology Clinic: Results of Quit Connect Dissemination Project
Healthcare Disparities in Rheumatology Poster- 9:00AM-11:00AM
-
Abstract Number: 0289
Endogenous Interferon-β and Low IL-4R on Transitional B Cells Promotes Lupus Nephritis